StefanBode

Cara Therapeutics - Outbreak or Selloff?

NASDAQ:CARA   Cara Therapeutics, Inc.
Cara Therapeutics is back on the strong resistance line that has been tested 4 times. Only once, in June 2017, was this briefly broken after FDA breakthrough therapy designation.
CR845 reduces itching in patients with chronic liver insufficiency. This brought in June 2018 3 large pharmaceutical companies on the plan, who wanted to market this product against once and milestone payments.

Outlook:
To confirm the breakout, a week-end above the blue resistance line is necessary. Following this, a retest of this resistance would be ideal to confirm this as a support zone.

If share price can not establish a weekly close above, is to expect a subsequent sale.

greeting
Stefan Bode

t.me/stefan_bode_analysen
Zins oder Dividende? Aktien oder Anleihen? Was sind Wandeloptionsanleihen?
Immobilien oder Rohstoffe?
Rinderfarm in Südamerika.
Geld richtig investieren!

www.fondslounge.de
Thông báo miễn trừ trách nhiệm

Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.